IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Apr 2025: Trial registered, NCT06915025
  2. 9 Jul 2025: Trial started, NCT06915025

The trials

NCT06915025: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

State
Under way
Phase
Phase 3
People
500 planned
Started
9 Jul 2025
Primary completion
31 Oct 2032
Arms
Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy
Results
None posted
  1. 7 Apr 2025: Trial registered
  2. 9 Jul 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.